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diagnosis of relapse by median 62 days (range 22-281). Of the
9 patients who started TPO as inpatient, 7 subsequently died
with median time from TPO to death 195 days (range 18-398).
No significant toxicities to TPO were identified. The median
time from TPO outpatient prescription to start was 22 days
due to insurance delays (range 8-40).
Conclusion: While causality is difficult to establish, TPO was
associated with improvement of platelet counts in a subset of
patients, with responses most likely to occur in outpatients
with viral reactivation, GvHD, or primary poor engraftment. In
5 patients with unidentified relapse, start of TPO preceded a
diagnosis of relapse by median 62 days. This should alert clini-
cians to assess for relapse when considering TPO. The start of
TPO in inpatients generally reflects grave clinical outlook given
low response rates and high number of subsequent deaths.184
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Background: Precise quantification of skeletal muscle using
computed tomography is accessible using cancer patients’ stan-
dard oncologic images. Reduced muscle mass (i.e. sarcopenia)
has been related to mortality, treatment complications and QOL
and reduced respiratory muscle strength, however these associ-
ations are not well characterized in adult alloHSCT recipients.
Methods: A consecutive retrospective series (n=296) patients
who had allogeneic BMT at a comprehensive Center between
01/2016 and 12/2017. Pre-transplant CT scans were used to
quantify skeletal muscle and adipose tissue at the 3rd lumbar
(L3) and/or 4th thoracic (T4) vertebra. Tumor and patient char-
acteristics were recorded, including FEV1 by spirometry. Sarco-
penia was defined according to Prado et al. (PMID:18539529)
Results: 296 patients (male n=161; female n=135) were
included, all of whom had thoracic-CT; a subset of these
(n=195) also had lumbar-CT. Diagnoses were NHL (n=172),
AML (n=66) HD (n=14), ALL (n=14), MDS (n=18) and other
(MM, MPN, CML; n=12).
Patients had increased BMI (male= 28.7 kg/m2, female =26.5
kg/m2), with many patients (<64.7%; ,57.0%) meeting criteria
for sarcopenia. Rates of sarcopenia were higher (p<0.001) than
in age- and sex-matched patients with solid tumors (male
56.4% n=1094; female 40.0%; n=685). Similar rates of sarcope-
nia (78%) were seen in in male BMT patients aged 50-60 years,
as had been reported in our population of male patients with
metastatic solid tumors aged 70-80 years (Kazemi-Bajestani
et al. PMID: 23819995).
Men and women were more muscular at T4 than L3. L3 and T4
skeletal muscle areas were moderately correlated (r2 =0.33-
0.47), as were L3 and T4 muscle radiodensities (r2 =0.58-0.63)
and subcutaneous fat areas (r2 =0.69- 0.71), (p<0.001).
In multivariable linear regression, independent predictors of
muscularity (i.e. T4 muscle index) were age (p=0.005), sex(p=0.000), BMI (p=0.000) and HCT-CI (p=0.057). Disease sever-
ity (Armand DRI) (p=0.131) was not significantly associated
with T4 muscle index. Similar conclusions were obtained for
L3 muscle index.
In multivariable linear regression adjusted for sex (p=0.000),
age (p=0.000) and HCT-CI (p=0.000) and both T4 muscle index
(b 0.252 [95%CI 0.126;0.412] p=0.000) and T4 muscle radio-
density (b 0.165 [95%CI 0.110;0.630] p=0.006) were indepen-
dently associated with FEV1; Armand DRI (p=0.712) and KPS
(p=0.991) were not associated with FEV1. Similar conclusions
were obtained when muscle index and radiodensity at L3 were
considered.
Discussion and Conclusion: Lumbar or thoracic CT images are
useful for body composition assessment in this population,
and reveal high rates of sarcopenia, similar to those reported
in very elderly patients. Reduced muscle mass and radio-
density associate with impaired FEV1. More muscular
patients were male, younger, of high BMI and had fewer
comorbidities.
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Introduction: Cytokine release syndrome (CRS) associated
with T-cell replete haplo-HSCT is characterized by fever and
high levels of inflammatory cytokines with symptom onset
occurring early after infusion. We report our analysis of CRS
development after T cell-replete haplo-HSCT after using pro-
phylactic dexamethasone.
Objetive: To evaluate the incidence of CRS with dexametha-
sone prophylaxis during an outpatient-based peripheral blood
haplo-HSCT, factors associated to CRS and its impact on trans-
plant outcomes.
Methods: Adults undergoing T-cell replete haplo-HSCT in our
transplant center between 2016-2018 were included. CRS was
graded using the criteria described by Lee et. al. Conditioning
was performed with fludarabine 25 mg/m2/day (day -5 to -3),
cyclophosphamide 350 mg/m2/day (day -5 to -3), and oral
melphalan 50-100 mg/m2 (day -2 to -1). Graft-versus-host dis-
ease (GVHD) prophylaxis consisted of post-transplant cyclo-
phosphamide (PTCy) 50 mg/kg (days +3 to +4) as well as
mycophenolate and either cyclosporine or tacrolimus starting
on day +5. Dexamethasone 8 mg IV was administered on day 0
to +2 as CRS prophylaxis.
Results: Forty two patients were included. The most common
underlying diagnosis was acute leukemia (n=22, 52%). Condi-
tioning was myeloablative (n=33, 79%) or reduced-intensity
(n=9, 21%). Thirty patients (71.4%) developed CRS. CRS severity
was grade 1/2 in n=28 (66.7%) and grade 3 in n=2 (4.8%).
Median time to onset occurred on day +2 (0-4) and usually
resolved after PTCy on day +5 (range, 1-11). CRS incidence was
not associated with CD34+ cells infused, DRI/HCT-CI scores, or
conditioning intensity. Time to neutrophil and platelet engraft-
ment were similar regardless of CRS. Hospitalization was
required in 36 cases (87%) while n=6 (13%) were followed in a
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Survival outcomes and GVHDwere similar (Table 1)
Conclusion: CRS was common despite dexamethasone pro-
phylaxis, and most were grade 1/2. None of the factors evalu-
ated were associated to CRS and it did not influence outcomes.
Completely ambulatory conduct of HSCT was limited by the
development of CRS. New strategies are required to prevent
CRS and hospitalizations associated with haplo-HSCT.Table 1









RIC 9 (21.4%) 1 (8.3%) 8 (26.7%)
Myeloablative 33 (78.6%) 11 (91.7%) 22 (73.3%)
Neutrophil engraftment, median days (range) 16 (12-32) 17 (12-32) 16 (13-29) 0.77
Platelet engraftment, median days (range) 17 (12-32) 15.5 (13-24) 18 (10-100) 0.36
1-year cumulative incidence cGVHD, % (95%CI) 43 (32-61) 60 (46-74) 29 (12-46) 0.42*
2-year overall survival, % (95%CI) 57 (45-69) 66 (57-75) 75 (63-87) 0.40*
CRS: Cytokine release syndrome; RIC: Reduced-intensity conditioning, cGVHD: chronic graft versus host disease.
* Kaplan-Meier method186
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Advances in allogeneic hematopoietic cell transplantation
(HCT) have led to significantly improved day 100 survival over
time. Longer-term (1 year) survival, however, has not
changed significantly. In an effort to improve outcomes and
identify patients (pts) at higher risk for 1-year mortality, we
created a day 100 risk assessment tool.
The Day 100 Risk Assessment tool includes 11 items: HCT-co-
morbidity index, distance from transplant center, perfor-
mance status (PS) at day 100, GVHD requiring systemic corti-
costeroids, infection requiring intravenous antimicrobials,
caregiver support, poor coping skills/motivation, substance
abuse, poor health literacy/access, medication compliance,
and “other” concerns from the care team. Pts were given a
point for each identified factor and categorized as low risk
(score 0-2) or high risk (score3). High risk pts were targeted
for closer follow up beyond 100 days. Cox regression was
used to identify risk factors for overall survival (OS) within
the first year after HCT.
Between 11/2015-6/2018, 208 pts underwent allogeneic HCT
and 161 pts survived without relapse at day 100 (Table).Median follow up is 12 months (range 3-33). 1-year OS for
low-risk pts was significantly better than for high-risk pts
(82% vs 68%, P=0.006; Figure). Multivariable analysis
accounting for both pre-transplant and Day 100 risk factors
identified older age (55), (HR 2.92, 95% CI 1.21-7.08,
P=0.017); high disease risk (HR 2.93, 95% CI 1.34-6.39,
P=0.007), and day 100 high-risk score (HR 2.29, 95% CI 1.17-
4.48, P=0.015) as significant factors for poor OS. Univariate
analysis of individual components of the day 100 risk score
identified poor PS at day 100, infection, and caregiving con-
cerns as significant variables, P<0.004. A second multivari-
able model including individual factors demonstrated that
poor PS (HR 2.68, P=0.013), infection (HR 2.57, P=0.009) and
older age (HR 2.55, P=0.041) remained significantly associ-
ated with poor OS.
In sum, we developed a Day 100 Risk Assessment tool and
identified factors occurring within the first 100 days beyond
